Anti-Human HGFR/c-MET Reference Antibody (STI-0607, RUO) (HY196136)

Name: Anti-Human HGFR/c-MET Reference Antibody (STI-0607, RUO)
Brand: abinScience
SKU: HY196136
Price: 370 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HY196136
Descripción	Anti-Human MET/c-Met/HGFR (STI-0607) (HY196136) is a research-grade recombinant antibody targeting Tyrosine-protein kinase Met. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG
ID de clon	STI-0607
Sistema de expresión	Mammalian cells
Objetivo	Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P08581
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	STI-0607, STI0607, STI0607
Fondo	Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).
Nota	For research use only. Not suitable for clinical or therapeutic use.